Published: June 02, 2026, 15:18 UTC
The Coalition for Epidemic Preparedness Innovations (CEPI) committed up to $50 million to Moderna on Monday to develop an mRNA vaccine against Bundibugyo ebolavirus (BDBV), as an outbreak in the Democratic Republic of the Congo shows no signs of slowing.
A vaccine platform repurposed
Moderna will apply the same mRNA platform technology that produced its COVID-19 vaccine in record time. The funding covers preclinical development and Phase 1 clinical testing of the BDBV candidate, plus preparations to scale manufacturing for potential Phase 2/3 trials if early results are positive. The speed of the mRNA platform — which can be reprogrammed for new viral targets by swapping out the genetic sequence — is the core rationale for the investment.
CEPI announced the funding alongside commitments for two other BDBV vaccine candidates, totaling just over $60 million in acceleration funding. The organization described the urgency in stark terms: it aims to “urgently accelerate development” of countermeasures against a virus that already has one approved vaccine (for the Zaire strain, Ervebo) but nothing specifically for Bundibugyo.
Why Bundibugyo matters
Bundibugyo ebolavirus is a distinct species of the Ebola family, first identified during an outbreak in Uganda in 2007. It causes viral hemorrhagic fever and is different enough from Zaire ebolavirus that existing vaccines and treatments developed for that strain may not be fully effective — a concern the WHO has flagged in its response to the current outbreak.
The current outbreak in the DRC, centered in Ituri province, was declared by the World Health Organization in May 2026 and has spread to multiple health zones. As of late May, the WHO reported over 100 confirmed cases with a rising case fatality rate, stretching local health infrastructure and complicating ring vaccination efforts that rely on the Zaire-strain Ervebo vaccine.
A test for platform preparedness
The CEPI-Moderna deal is also a test of the “platform preparedness” concept that gained momentum after COVID-19. The idea is straightforward: instead of designing vaccines from scratch during each outbreak, develop a platform (mRNA, viral vector, protein subunit) that can be rapidly adapted to new pathogens. CEPI has invested heavily in this strategy since 2017, funding multiple platform technologies for what it calls “Disease X” preparedness.
BDBV is not Disease X — it’s a known filovirus with a finite outbreak history — but it represents exactly the kind of threat the platform approach was designed to handle: a pathogen with pandemic potential that lacks a dedicated vaccine and is currently spreading in a fragile health system.
The practical questions are whether Moderna can move from sequence to Phase 1 faster than traditional vaccine development — and whether the manufacturing ramp funded now will be ready if Phase 1 succeeds while the outbreak is still active.
Sources: [Ars Technica](https://arstechnica.com/health/2026/06/moderna-gets-50-million-to-develop-mrna-ebola-vaccine-against-bundibugyo/) (June 2, 2026); [CEPI](https://cepi.net/) (June 1, 2026); [WHO Situation Report](https://www.who.int) (May 2026)